{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:23:04Z","timestamp":1795094584871,"version":"4.10.2"},"reference-count":181,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1038\/s41571-026-01209-z","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:39:03Z","timestamp":1791286743000},"page":"962-982","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the immunological effects of antibody\u2013drug conjugates"],"prefix":"10.1038","volume":"23","author":[{"given":"Paola","family":"Zagami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7310-7824","authenticated-orcid":false,"given":"Antonio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-4649","authenticated-orcid":false,"given":"Lisa Anne","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"1209_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"1209_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102395","volume":"106","author":"E Nicol\u00f2","year":"2022","unstructured":"Nicol\u00f2, E. et al. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat. Rev. 106, 102395 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"1209_CR3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/CCO.0000000000000656","volume":"32","author":"E Nicol\u00f2","year":"2020","unstructured":"Nicol\u00f2, E., Zagami, P. & Curigliano, G. Antibody\u2013drug conjugates in breast cancer: the chemotherapy of the future? Curr. Opin. Oncol. 32, 494\u2013502 (2020).","journal-title":"Curr. Opin. Oncol."},{"key":"1209_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","volume":"29","author":"HA Burris","year":"2011","unstructured":"Burris, H. A. et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29, 398\u2013405 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","volume":"42","author":"G Curigliano","year":"2024","unstructured":"Curigliano, G. et al. Trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): primary results from DESTINY-Breast06 (DB-06) [abstract]. J. Clin. Oncol. 42, LBA1000 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2203690 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1209_CR7","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/j.annonc.2022.03.277","volume":"33","author":"MF Mosele","year":"2022","unstructured":"Mosele, M. F. et al. Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial [abstract LBA1]. Ann. Oncol. 33, S123 (2022).","journal-title":"Ann. Oncol."},{"key":"1209_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2229101","volume":"15","author":"H Maecker","year":"2023","unstructured":"Maecker, H., Jonnalagadda, V., Bhakta, S., Jammalamadaka, V. & Junutula, J. R. Exploration of the antibody\u2013drug conjugate clinical landscape. MAbs 15, 2229101 (2023).","journal-title":"MAbs"},{"key":"1209_CR9","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1158\/1078-0432.CCR-20-4513","volume":"27","author":"GD Demetri","year":"2021","unstructured":"Demetri, G. D. et al. First-in-human phase I study of ABBV-085, an antibody\u2013drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors. Clin. Cancer Res. 27, 3556\u20133566 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1209_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/cancers11030394","volume":"11","author":"D Collins","year":"2019","unstructured":"Collins, D., Bossenmaier, B., Kollmorgen, G. & Niederfellner, G. Acquired resistance to antibody-drug conjugates. Cancers 11, 394 (2019).","journal-title":"Cancers"},{"key":"1209_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19498-y","volume":"11","author":"G Lu","year":"2020","unstructured":"Lu, G. et al. Co-administered antibody improves penetration of antibody\u2013dye conjugate into human cancers with implications for antibody\u2013drug conjugates. Nat. Commun. 11, 5667 (2020).","journal-title":"Nat. Commun."},{"key":"1209_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020396","volume":"14","author":"R Sheyi","year":"2022","unstructured":"Sheyi, R., de la Torre, B. G. & Albericio, F. Linkers: an assurance for controlled delivery of antibody-drug conjugate. Pharmaceutics 14, 396 (2022).","journal-title":"Pharmaceutics"},{"key":"1209_CR13","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1158\/0008-5472.CAN-07-3018","volume":"68","author":"GM Thurber","year":"2008","unstructured":"Thurber, G. M. & Wittrup, K. D. Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res. 68, 3334\u20133341 (2008).","journal-title":"Cancer Res."},{"key":"1209_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/B978-0-12-396962-0.00010-0","volume":"503","author":"KD Wittrup","year":"2012","unstructured":"Wittrup, K. D., Thurber, G. M., Schmidt, M. M. & Rhoden, J. J. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol. 503, 255\u2013268 (2012).","journal-title":"Methods Enzymol."},{"key":"1209_CR15","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber, G. M., Schmidt, M. M. & Wittrup, K. D. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug. Deliv. Rev. 60, 1421\u20131434 (2008).","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"1209_CR16","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0391-1","volume":"22","author":"B Menezes","year":"2020","unstructured":"Menezes, B., Cilliers, C., Wessler, T., Thurber, G. M. & Linderman, J. J. An agent-based systems pharmacology model of the antibody-drug conjugate kadcyla to predict efficacy of different dosing regimens. AAPS J. 22, 29 (2020).","journal-title":"AAPS J."},{"key":"1209_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.836925","volume":"13","author":"S Dong","year":"2022","unstructured":"Dong, S., Nessler, I., Kopp, A., Rubahamya, B. & Thurber, G. M. Predictive simulations in preclinical oncology to guide the translation of biologics. Front. Pharmacol. 13, 836925 (2022).","journal-title":"Front. Pharmacol."},{"key":"1209_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1304365","volume":"14","author":"T Damelang","year":"2024","unstructured":"Damelang, T. et al. Impact of structural modifications of IgG antibodies on effector functions. Front. Immunol. 14, 1304365 (2024).","journal-title":"Front. Immunol."},{"key":"1209_CR19","doi-asserted-by":"publisher","unstructured":"Thurber, G. M. Tumor effect-site pharmacokinetics: mechanisms and impact on efficacy. In Pharmaceutical Sciences Encyclopedia (ed. Gad, S.C.) https:\/\/doi.org\/10.1002\/9780470571224.pse551 (Wiley, 2015).","DOI":"10.1002\/9780470571224.pse551"},{"key":"1209_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1208\/s12248-016-9940-z","volume":"18","author":"C Cilliers","year":"2016","unstructured":"Cilliers, C., Guo, H., Liao, J., Christodolu, N. & Thurber, G. M. Multiscale modeling of antibody-drug conjugates: connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy. AAPS J. 18, 1117\u20131130 (2016).","journal-title":"AAPS J."},{"key":"1209_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.4049\/jimmunol.1701302","volume":"200","author":"OJ Finn","year":"2018","unstructured":"Finn, O. J. A believer\u2019s overview of cancer immunosurveillance and Immunotherapy. J. Immunol. 200, 385\u2013391 (2018).","journal-title":"J. Immunol."},{"key":"1209_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487\u2013500 (2022).","journal-title":"Nat. Immunol."},{"key":"1209_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51\u201372 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"1209_CR24","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","volume":"14","author":"A Ahmed","year":"2020","unstructured":"Ahmed, A. & Tait, S. W. G. Targeting immunogenic cell death in cancer. Mol. Oncol. 14, 2994\u20133006 (2020).","journal-title":"Mol. Oncol."},{"key":"1209_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486\u2013541 (2018).","journal-title":"Cell Death Differ."},{"key":"1209_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00588","volume":"6","author":"AD Garg","year":"2015","unstructured":"Garg, A. D. et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front. Immunol. 6, 588 (2015).","journal-title":"Front. Immunol."},{"key":"1209_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1565859","volume":"8","author":"M Bauzon","year":"2019","unstructured":"Bauzon, M. et al. Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells. Oncoimmunology 8, e1565859 (2019).","journal-title":"Oncoimmunology"},{"key":"1209_CR28","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","volume":"77","author":"J Rios-Doria","year":"2017","unstructured":"Rios-Doria, J. et al. Antibody\u2013drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies. Cancer Res. 77, 2686\u20132698 (2017).","journal-title":"Cancer Res."},{"key":"1209_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0464-1","volume":"7","author":"L D\u2019Amico","year":"2019","unstructured":"D\u2019Amico, L. et al. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J. Immunother. Cancer 7, 16 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1209_CR30","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.954460","volume":"3","author":"P M\u00fcller","year":"2014","unstructured":"M\u00fcller, P., Martin, K., Theurich, S., von Bergwelt-Baildon, M. & Zippelius, A. Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity. Oncoimmunology 3, e954460 (2014).","journal-title":"Oncoimmunology"},{"key":"1209_CR31","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1182\/blood-2005-03-1161","volume":"106","author":"N Mizumoto","year":"2005","unstructured":"Mizumoto, N. et al. Discovery of novel immunostimulants by dendritic-cell-based functional screening. Blood 106, 3082\u20133089 (2005).","journal-title":"Blood"},{"key":"1209_CR32","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.clbc.2021.04.011","volume":"21","author":"EP Hamilton","year":"2021","unstructured":"Hamilton, E. P. et al. Impact of anti-HER2 treatments combined with atezolizumab on the tumor immune microenvironment in early or metastatic breast cancer: results from a phase Ib study. Clin. Breast Cancer 21, 539\u2013551 (2021).","journal-title":"Clin. Breast Cancer"},{"key":"1209_CR33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","volume":"2","author":"P M\u00fcller","year":"2014","unstructured":"M\u00fcller, P. et al. Microtubule-depolymerizing agents used in antibody\u2013drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol. Res. 2, 741\u2013755 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"1209_CR34","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1016\/j.celrep.2019.08.057","volume":"28","author":"AS Kashyap","year":"2019","unstructured":"Kashyap, A. S. et al. GEF-H1 signaling upon microtubule destabilization is required for dendritic cell activation and specific anti-tumor responses. Cell Rep. 28, 3367\u20133380.e8 (2019).","journal-title":"Cell Rep."},{"key":"1209_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"L-C Tsao","year":"2025","unstructured":"Tsao, L.-C. et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat. Commun. 16, 3167 (2025).","journal-title":"Nat. Commun."},{"key":"1209_CR36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.15698\/cst2025.08.311","volume":"9","author":"S Forveille","year":"2025","unstructured":"Forveille, S., Leduc, M., Sauvat, A., Kroemer, G. & Kepp, O. Datopotamab deruxtecan induces hallmarks of immunogenic cell death. Cell Stress 9, 194\u2013200 (2025).","journal-title":"Cell Stress"},{"key":"1209_CR37","doi-asserted-by":"publisher","first-page":"315ra188","DOI":"10.1126\/scitranslmed.aac4925","volume":"7","author":"P M\u00fcller","year":"2015","unstructured":"M\u00fcller, P. et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4\/PD-1 blockade. Sci. Transl. Med. 7, 315ra188 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1209_CR38","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.annonc.2023.05.004","volume":"34","author":"M Oliveira","year":"2023","unstructured":"Oliveira, M. et al. Patritumab deruxtecan in untreated hormone receptor-positive\/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study. Ann. Oncol. 34, 670\u2013680 (2023).","journal-title":"Ann. Oncol."},{"key":"1209_CR39","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1038\/s41591-025-03885-3","volume":"31","author":"B Pistilli","year":"2025","unstructured":"Pistilli, B. et al. Patritumab deruxtecan in HR+HER2\u2212 advanced breast cancer: a phase 2 trial. Nat. Med. 31, 3492\u20133503 (2025).","journal-title":"Nat. Med."},{"key":"1209_CR40","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","volume":"25","author":"A Zippelius","year":"2025","unstructured":"Zippelius, A., Tolaney, S. M., Tarantino, P., Balthasar, J. P. & Thurber, G. M. Unveiling the molecular and immunological drivers of antibody\u2013drug conjugates in cancer treatment. Nat. Rev. Cancer 25, 925\u2013944 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"1209_CR41","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1245\/s10434-011-1667-6","volume":"18","author":"AJ Russ","year":"2011","unstructured":"Russ, A. J. et al. Suppression of T-cell expansion by melanoma is exerted on resting cells. Ann. Surg. Oncol. 18, 3848\u20133857 (2011).","journal-title":"Ann. Surg. Oncol."},{"key":"1209_CR42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","volume":"25","author":"GA Rabinovich","year":"2007","unstructured":"Rabinovich, G. A., Gabrilovich, D. & Sotomayor, E. M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267\u2013296 (2007).","journal-title":"Annu. Rev. Immunol."},{"key":"1209_CR43","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","volume":"17","author":"TN Iwata","year":"2018","unstructured":"Iwata, T. N. et al. A HER2-targeting antibody\u2013drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol. Cancer Ther. 17, 1494\u20131503 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"1209_CR44","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","volume":"23","author":"RA Heiser","year":"2024","unstructured":"Heiser, R. A. et al. Brentuximab vedotin-driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity. Mol. Cancer Ther. 23, 68\u201383 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"1209_CR45","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.chembiol.2021.02.013","volume":"28","author":"L Xia","year":"2021","unstructured":"Xia, L. et al. HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells. Cell Chem. Biol. 28, 610\u2013624.e5 (2021).","journal-title":"Cell Chem. Biol."},{"key":"1209_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 5, 520 (2014).","journal-title":"Front. Immunol."},{"key":"1209_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","volume":"24","author":"F Galvez-Cancino","year":"2024","unstructured":"Galvez-Cancino, F. et al. Fc\u03b3 receptors and immunomodulatory antibodies in cancer. Nat. Rev. Cancer 24, 51\u201371 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"1209_CR48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-bioeng-071114-040733","volume":"17","author":"KE Tiller","year":"2015","unstructured":"Tiller, K. E. & Tessier, P. M. Advances in antibody design. Annu. Rev. Biomed. Eng. 17, 191\u2013216 (2015).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"1209_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00876-4","volume":"13","author":"J Yu","year":"2020","unstructured":"Yu, J., Song, Y. & Tian, W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J. Hematol. Oncol. 13, 45 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"1209_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1395127","volume":"7","author":"RM Hoffmann","year":"2018","unstructured":"Hoffmann, R. M. et al. Antibody structure and engineering considerations for the design and function of antibody drug conjugates (ADCs). Oncoimmunology 7, e1395127 (2018).","journal-title":"Oncoimmunology"},{"key":"1209_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.641521","volume":"12","author":"A Karampatzakis","year":"2021","unstructured":"Karampatzakis, A. et al. Antibody afucosylation augments CD16-mediated serial killing and IFN\u03b3 secretion by human natural killer cells. Front. Immunol. 12, 641521 (2021).","journal-title":"Front. Immunol."},{"key":"1209_CR52","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-1766","volume":"82","author":"S Anderson","year":"2022","unstructured":"Anderson, S. et al. SGN-ALPV a novel, investigational vedotin ADC demonstrates highly effective targeting of oncofetal phosphatases ALPP and ALPPL2 in preclinical models [abstract]. Cancer Res. 82, 1766 (2022).","journal-title":"Cancer Res."},{"key":"1209_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","volume":"39","author":"M Aoyama","year":"2022","unstructured":"Aoyama, M., Tada, M., Yokoo, H., Demizu, Y. & Ishii-Watabe, A. Fc\u03b3 receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates. Pharm. Res. 39, 89\u2013103 (2022).","journal-title":"Pharm. Res."},{"key":"1209_CR54","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","volume":"128","author":"TT Junttila","year":"2011","unstructured":"Junttila, T. T., Li, G., Parsons, K., Phillips, G. L. & Sliwkowski, M. X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 128, 347\u2013356 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"1209_CR55","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y. et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res. 22, 5097\u20135108 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1209_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13036-026-00735-9","author":"S Kim","year":"2026","unstructured":"Kim, S. et al. A stealth-body Fc engineering platform enables complete effector silencing in antibody and ADC therapeutics. J. Biol. Eng. https:\/\/doi.org\/10.1186\/s13036-026-00735-9 (2026).","journal-title":"J. Biol. Eng."},{"key":"1209_CR57","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-17-0019","volume":"16","author":"F Li","year":"2017","unstructured":"Li, F. et al. Tumor-associated macrophages can contribute to antitumor activity through Fc\u03b3R-mediated processing of antibody\u2013drug conjugates. Mol. Cancer Ther. 16, 1347\u20131354 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"1209_CR58","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2024024442","volume":"144","author":"RP Taylor","year":"2024","unstructured":"Taylor, R. P. & Lindorfer, M. A. Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms. Blood 144, 137\u2013144 (2024).","journal-title":"Blood"},{"key":"1209_CR59","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00262-014-1565-4","volume":"63","author":"K Martin","year":"2014","unstructured":"Martin, K. et al. The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. Cancer Immunol. Immunother. 63, 925\u2013938 (2014).","journal-title":"Cancer Immunol. Immunother."},{"key":"1209_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030496","volume":"17","author":"Y Jiang","year":"2025","unstructured":"Jiang, Y., Dong, S. & Wang, Y. Antibody\u2013drug conjugates targeting CD30 in T-cell lymphomas: clinical progression and mechanism. Cancers 17, 496 (2025).","journal-title":"Cancers"},{"key":"1209_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16173071","volume":"16","author":"C Taylor","year":"2024","unstructured":"Taylor, C. et al. Mechanistic insights into the successful development of combination therapy of enfortumab vedotin and pembrolizumab for the treatment of locally advanced or metastatic urothelial cancer. Cancers 16, 3071 (2024).","journal-title":"Cancers"},{"key":"1209_CR62","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-5581","volume":"80","author":"BA Liu","year":"2020","unstructured":"Liu, B. A. et al. Enfortumab vedotin, an anti-nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers [abstract]. Cancer Res. 80, 5581 (2020).","journal-title":"Cancer Res."},{"key":"1209_CR63","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1158\/0008-5472.CAN-23-2812","volume":"84","author":"ME Gedik","year":"2024","unstructured":"Gedik, M. E. et al. Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer. Cancer Res. 84, 1475\u20131490 (2024).","journal-title":"Cancer Res."},{"key":"1209_CR64","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1182\/blood-2024-198060","volume":"144","author":"M Tomita","year":"2024","unstructured":"Tomita, M. et al. Infiltration of innate immune cells into tumors by polatuzumab vedotin treatment contributes to its antitumor effect in xenograft and syngeneic mouse models [abstract]. Blood 144, 4166 (2024).","journal-title":"Blood"},{"key":"1209_CR65","doi-asserted-by":"publisher","first-page":"6978","DOI":"10.1158\/0008-5472.CAN-09-1101","volume":"69","author":"H Tanaka","year":"2009","unstructured":"Tanaka, H., Matsushima, H., Mizumoto, N. & Takashima, A. Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. Cancer Res. 69, 6978\u20136986 (2009).","journal-title":"Cancer Res."},{"key":"1209_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96521-2","volume":"11","author":"S Nakajima","year":"2021","unstructured":"Nakajima, S. et al. The effects of T-DXd on the expression of HLA class I and chemokines CXCL9\/10\/11 in HER2-overexpressing gastric cancer cells. Sci. Rep. 11, 16891 (2021).","journal-title":"Sci. Rep."},{"key":"1209_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01893-3","volume":"22","author":"K-S Oh","year":"2024","unstructured":"Oh, K.-S. et al. Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells. Cell Commun. Signal. 22, 518 (2024).","journal-title":"Cell Commun. Signal."},{"key":"1209_CR68","doi-asserted-by":"publisher","first-page":"B009","DOI":"10.1158\/2326-6074.TUMIMM24-B009","volume":"12","author":"L-C Tsao","year":"2024","unstructured":"Tsao, L.-C. et al. Enhancing antitumor immune responses: trastuzumab deruxtecan (T-DXd) induces immunogenic cell death and phagocytosis, synergizing with CD47\/SIRP\u03b1 checkpoint blockade [abstract]. Cancer Immunol. Res. 12, B009 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"1209_CR69","first-page":"45","volume":"21","author":"J Zhang","year":"2024","unstructured":"Zhang, J., Yu, S., Peng, Q., Wang, P. & Fang, L. Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies. Cancer Biol. Med. 21, 45\u201364 (2024).","journal-title":"Cancer Biol. Med."},{"key":"1209_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072114","volume":"15","author":"K Fukuda","year":"2023","unstructured":"Fukuda, K. Immune regulation by cytosolic DNA sensors in the tumor microenvironment. Cancers 15, 2114 (2023).","journal-title":"Cancers"},{"key":"1209_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304985","volume":"19","author":"M Sue","year":"2024","unstructured":"Sue, M. et al. Blockade of SIRP\u03b1-CD47 axis by anti-SIRP\u03b1 antibody enhances anti-tumor activity of DXd antibody-drug conjugates. PLoS ONE 19, e0304985 (2024).","journal-title":"PLoS ONE"},{"key":"1209_CR72","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1535-7163.MCT-21-0580","volume":"21","author":"E Khera","year":"2022","unstructured":"Khera, E. et al. Cellular-resolution imaging of bystander payload tissue penetration from antibody-drug conjugates. Mol. Cancer Ther. 21, 310\u2013321 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"1209_CR73","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","volume":"21","author":"LA Emens","year":"2020","unstructured":"Emens, L. A. et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 21, 1283\u20131295 (2020).","journal-title":"Lancet Oncol."},{"key":"1209_CR74","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS23-PO3-20-01","volume":"84","author":"P Schmid","year":"2024","unstructured":"Schmid, P. et al. ASTEFANIA: a phase III study of ado-trastuzumab emtansine plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy [abstract]. Cancer Res. 84, PO3-20-01 (2024).","journal-title":"Cancer Res."},{"key":"1209_CR75","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS19-PD1-05","volume":"80","author":"EP Hamilton","year":"2020","unstructured":"Hamilton, E. P. et al. Atezolizumab in combination with trastuzumab emtansine or with trastuzumab and pertuzumab in patients with HER2-positive breast cancer and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer: safety and biomarker outcomes from a multi-cohort Phase Ib study [abstract]. Cancer Res. 80, PD1-05 (2020).","journal-title":"Cancer Res."},{"key":"1209_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005119","volume":"10","author":"AG Waks","year":"2022","unstructured":"Waks, A. G. et al. Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. J. Immunother. Cancer 10, e005119 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1209_CR77","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","volume":"30","author":"E Hamilton","year":"2024","unstructured":"Hamilton, E. et al. Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105 study. Clin. Cancer Res. 30, 5548\u20135558 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1209_CR78","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-P5-07-29","volume":"31","author":"HS Rugo","year":"2025","unstructured":"Rugo, H. S. et al. Trastuzumab deruxtecan with pembrolizumab in previously treated HER2-expressing advanced or metastatic breast cancer: interim analyses of the breast cohorts from the open-label, multicenter, phase 1b study DS8201-A-U106 [abstract]. Clin. Cancer Res. 31, P5-07-29 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1209_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2024.100747","volume":"24","author":"A Italiano","year":"2024","unstructured":"Italiano, A. et al. Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): interim analysis of a phase Ib study [abstract 118MO]. Immunooncol. Technol. 24, 100747 (2024).","journal-title":"Immunooncol. Technol."},{"key":"1209_CR80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.295","volume":"40","author":"YY Janjigian","year":"2022","unstructured":"Janjigian, Y. Y. et al. Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced\/metastatic HER2\u2009+\u2009gastric cancer (GC)\/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 [abstract]. J. Clin. Oncol. 40, 295 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.448","volume":"43","author":"YY Janjigian","year":"2025","unstructured":"Janjigian, Y. Y. et al. Updated results from the trastuzumab deruxtecan (T-DXd) 5.4\u2009mg\/kg triplet combination of DESTINY-Gastric03 (DG-03): first-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced\/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA) [abstract]. J. Clin. Oncol. 43, 448 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.4022","volume":"44","author":"YY Janjigian","year":"2026","unstructured":"Janjigian, Y. Y. et al. First-line (1L) trastuzumab deruxtecan (T-DXd)\u2013based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): safety results from DESTINY-Gastric03 (DG-03) part 2 arms D and F, and part 4 [abstract]. J. Clin. Oncol. 44, 4022 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR83","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8617","volume":"42","author":"BP Levy","year":"2024","unstructured":"Levy, B. P. et al. Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1\u2009L) therapy for advanced non-small cell lung cancer (aNSCLC): subgroup analysis from TROPION-Lung02 [abstract]. J. Clin. Oncol. 42, 8617 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2026.103688","volume":"21","author":"B Levy","year":"2026","unstructured":"Levy, B. et al. Datopotamab deruxtecan plus pembrolizumab with or without platinum-based chemotherapy for advanced or metastatic NSCLC: the phase Ib TROPION-Lung02 trial. J. Thorac. Oncol. 21, 103688 (2026).","journal-title":"J. Thorac. Oncol."},{"key":"1209_CR85","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/j.annonc.2023.09.556","volume":"34","author":"P Schmid","year":"2023","unstructured":"Schmid, P. et al. Datopotamab deruxtecan (Dato-DXd)\u2009+\u2009durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): updated results from BEGONIA, a phase Ib\/II study [abstract 379MO]. Ann. Oncol. 34, S337 (2023).","journal-title":"Ann. Oncol."},{"key":"1209_CR86","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1016\/j.annonc.2022.03.185","volume":"33","author":"P Schmid","year":"2022","unstructured":"Schmid, P. et al. Datopotamab deruxtecan (Dato-DXd)\u2009+\u2009durvalumab (D) as first-line (1\u2009L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): initial results from BEGONIA, a phase Ib\/II study [abstract 166MO]. Ann. Oncol. 33, S199 (2022).","journal-title":"Ann. Oncol."},{"key":"1209_CR87","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.annonc.2026.05.693","volume":"37","author":"P Schmid","year":"2026","unstructured":"Schmid, P. et al. Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib\/II BEGONIA study. Ann. Oncol. 37, 1081\u20131092 (2026).","journal-title":"Ann. Oncol."},{"key":"1209_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103203","volume":"9","author":"P Schmid","year":"2024","unstructured":"Schmid, P. et al. Interim analysis (IA) of the atezolizumab (atezo)\u2009+\u2009sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: a phase Ib\/II study of multiple treatment (tx) combinations in pts with locally advanced\/metastatic BC (LA\/mBC) [abstract 181O]. ESMO Open\u00a09, 103203 (2024).","journal-title":"ESMO Open"},{"key":"1209_CR89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","volume":"43","author":"SM Tolaney","year":"2025","unstructured":"Tolaney, S. M. et al. Sacituzumab govitecan (SG)\u2009+\u2009pembrolizumab (pembro) vs chemotherapy (chemo)\u2009+\u2009pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study [abstract]. J. Clin. Oncol. 43, LBA109 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1004","volume":"42","author":"AC Garrido-Castro","year":"2024","unstructured":"Garrido-Castro, A. C. et al. SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive\/HER2-negative breast cancer [abstract]. J. Clin. Oncol. 42, LBA1004 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.06.012","author":"AC Garrido-Castro","year":"2026","unstructured":"Garrido-Castro, A. C. et al. SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive\/HER2-negative breast cancer. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2026.06.012 (2026).","journal-title":"Ann. Oncol."},{"key":"1209_CR92","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes, C. J. et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J. Clin. Oncol. 41, 22\u201331 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR93","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.22.02887","volume":"41","author":"PH O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell, P. H. et al. Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer. J. Clin. Oncol. 41, 4107\u20134117 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR94","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875\u2013888 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1209_CR95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.664","volume":"43","author":"T Powles","year":"2025","unstructured":"Powles, T. et al. EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la\/mUC) [abstract]. J. Clin. Oncol. 43, 664 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR96","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","volume":"36","author":"L Zhou","year":"2025","unstructured":"Zhou, L. et al. Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study. Ann. Oncol. 36, 331\u2013339 (2025).","journal-title":"Ann. Oncol."},{"key":"1209_CR97","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","volume":"393","author":"X Sheng","year":"2025","unstructured":"Sheng, X. et al. Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer. N. Engl. J. Med. 393, 2324\u20132337 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1209_CR98","doi-asserted-by":"publisher","first-page":"S1138","DOI":"10.1016\/j.annonc.2024.08.2052","volume":"35","author":"MD Galsky","year":"2024","unstructured":"Galsky, M. D. et al. Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la\/mUC): RC48G001 cohort C [abstract 1967MO]. Ann. Oncol. 35, S1138\u2013S1139 (2024).","journal-title":"Ann. Oncol."},{"key":"1209_CR99","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1200\/JCO.23.00720","volume":"41","author":"I Vergote","year":"2023","unstructured":"Vergote, I. et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 study. J. Clin. Oncol. 41, 5536\u20135549 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR100","doi-asserted-by":"publisher","first-page":"S721","DOI":"10.1016\/j.annonc.2025.08.1802","volume":"36","author":"BJ Monk","year":"2025","unstructured":"Monk, B. J. et al. Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 study [abstract 1166P]. Ann. Oncol. 36, S721 (2025).","journal-title":"Ann. Oncol."},{"key":"1209_CR101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.726","volume":"43","author":"G Zhang","year":"2025","unstructured":"Zhang, G., Fu, Q., Zhang, F., Yang, F. & Hou, H. Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment for patients with locally advanced muscle-invasive bladder cancer: a mono-institutional retrospective study [abstract]. J. Clin. Oncol. 43, 726 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR102","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1038\/s41591-024-03267-1","volume":"30","author":"RA Shatsky","year":"2024","unstructured":"Shatsky, R. A. et al. Datopotamab\u2013deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat. Med. 30, 3737\u20133747 (2024).","journal-title":"Nat. Med."},{"key":"1209_CR103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511674","author":"C Vulsteke","year":"2026","unstructured":"Vulsteke, C. et al. Perioperative enfortumab vedotin and pembrolizumab in bladder cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2511674 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1209_CR104","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa2601486","volume":"395","author":"MD Galsky","year":"2026","unstructured":"Galsky, M. D. et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. N. Engl. J. Med. 395, 338\u2013348 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1209_CR105","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S1470-2045(26)00050-1","volume":"27","author":"A Necchi","year":"2026","unstructured":"Necchi, A. et al. Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study. Lancet Oncol. 27, 442\u2013451 (2026).","journal-title":"Lancet Oncol."},{"key":"1209_CR106","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.1013","volume":"44","author":"SM Tolaney","year":"2026","unstructured":"Tolaney, S. M. et al. ASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan (SG)\u2009+\u2009pembrolizumab (pembro) vs chemotherapy (chemo)\u2009+\u2009pembro in participants (pts) with previously untreated PD-L1\u2009+\u2009metastatic triple-negative breast cancer (mTNBC) [abstract]. J. Clin. Oncol. 44, 1013 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR107","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00766","author":"ZI Ozay","year":"2024","unstructured":"Ozay, Z. I., Hage Chehade, C., Agarwal, N. & Swami, U. Assessing nectin-4 as a predictive biomarker in urothelial carcinoma and other genitourinary malignancies. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO-24-00766 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"1209_CR108","first-page":"A789","volume":"10","author":"J Powderly","year":"2022","unstructured":"Powderly, J., Kaminker, P., Zhao, E., Casey, D. & Shenderov, E. A phase 1\/1b dose escalation and cohort expansion study of MGC018 in combination with lorigerlimab in patients with advanced solid tumors (AST) [abstract 757]. J. Immunother. Cancer 10, A789 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1209_CR109","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8521","volume":"43","author":"SN Waqar","year":"2025","unstructured":"Waqar, S. N. et al. First-line (1L) datopotamab deruxtecan (Dato-DXd)\u2009+\u2009rilvegostomig in advanced or metastatic non-small cell lung cancer (a\/mNSCLC): Results from TROPION-Lung04 (cohort 5) [abstract]. J. Clin. Oncol. 43, 8521 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR110","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama, K., Anami, Y., Ha, S. Y. Y. & Yamazaki, C. M. Exploring the next generation of antibody\u2013drug conjugates. Nat. Rev. Clin. Oncol. 21, 203\u2013223 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1209_CR111","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","volume":"30","author":"LE Budde","year":"2024","unstructured":"Budde, L. E. et al. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial. Nat. Med. 30, 229\u2013239 (2024).","journal-title":"Nat. Med."},{"key":"1209_CR112","doi-asserted-by":"publisher","first-page":"S758","DOI":"10.1016\/S2152-2650(25)02300-6","volume":"25","author":"JP Alderuccio","year":"2025","unstructured":"Alderuccio, J. P. et al. Initial results from LOTIS-7: a phase 1b study of loncastuximab tesirine plus glofitamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) [abstract ABCL-777]. Clin. Lymphoma Myeloma Leuk. 25, S758 (2025).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1209_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-0972-7","volume":"3","author":"R Arulanandam","year":"2020","unstructured":"Arulanandam, R. et al. The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy. Commun. Biol. 3, 254 (2020).","journal-title":"Commun. Biol."},{"key":"1209_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-11648-0","volume":"12","author":"R Evans","year":"2022","unstructured":"Evans, R. & Thurber, G. M. Design of high avidity and low affinity antibodies for in situ control of antibody drug conjugate targeting. Sci. Rep. 12, 7677 (2022).","journal-title":"Sci. Rep."},{"key":"1209_CR115","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/1535-7163.MCT-25-0576","volume":"25","author":"A Kopp","year":"2026","unstructured":"Kopp, A. et al. In vivo auto-tuning of antibody\u2013drug conjugate delivery to maximize efficacy using high-avidity, low-affinity antibodies. Mol. Cancer Ther. 25, 610\u2013621 (2026).","journal-title":"Mol. Cancer Ther."},{"key":"1209_CR116","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1074\/jbc.M113.513366","volume":"289","author":"Z Liu","year":"2014","unstructured":"Liu, Z. et al. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies. J. Biol. Chem. 289, 3571\u20133590 (2014).","journal-title":"J. Biol. Chem."},{"key":"1209_CR117","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1517\/14712598.2014.920814","volume":"14","author":"KR Polu","year":"2014","unstructured":"Polu, K. R. & Lowman, H. B. Probody therapeutics for targeting antibodies to diseased tissue. Expert. Opin. Biol. Ther. 14, 1049\u20131053 (2014).","journal-title":"Expert. Opin. Biol. Ther."},{"key":"1209_CR118","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-21-0194","volume":"27","author":"M Johnson","year":"2021","unstructured":"Johnson, M. et al. Phase I, first-in-human study of the probody therapeutic CX-2029 in adults with advanced solid tumor malignancies. Clin. Cancer Res. 27, 4521\u20134530 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1209_CR119","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1535-7163.MCT-21-0193","volume":"21","author":"S Singh","year":"2022","unstructured":"Singh, S. et al. Nonclinical efficacy and safety of CX-2029, an anti-CD71 probody\u2013drug conjugate. Mol. Cancer Ther. 21, 1326\u20131336 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"1209_CR120","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-21-3656","volume":"28","author":"V Boni","year":"2022","unstructured":"Boni, V. et al. Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase I\/II Trial. Clin. Cancer Res. 28, 2020\u20132029 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1209_CR121","unstructured":"CytomX Therapeutics. CytomX\u2019s varsetatug masetecan (EpCAM PROBODY\u00ae ADC) continues to demonstrate positive data supporting potential as a new treatment option in late-line colorectal cancer. GlobeNewswire https:\/\/tinyurl.com\/mtxhy6t7 (2026)."},{"key":"1209_CR122","first-page":"A690","volume":"13","author":"B Povinelli","year":"2025","unstructured":"Povinelli, B. et al. Pharmacodynamic activity of CX-801, a masked IFN\u03b12b PROBODY\u00ae cytokine, in patients with advanced melanoma [abstract 606]. J. Immunother. Cancer 13, A690 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"1209_CR123","doi-asserted-by":"publisher","first-page":"S483","DOI":"10.1016\/j.annonc.2023.09.1879","volume":"34","author":"Y Shan","year":"2023","unstructured":"Shan, Y. et al. Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1\/PD-L1 refractory\/resistant models [abstract 693P]. Ann. Oncol. 34, S483 (2023).","journal-title":"Ann. Oncol."},{"key":"1209_CR124","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.6060","volume":"44","author":"J Ma","year":"2026","unstructured":"Ma, J. et al. Efficacy and safety of HLX43 (an anti\u2013PD-L1 ADC) in previously treated recurrent\/metastatic nasopharyngeal carcinoma: a multicenter, randomized phase 2 study [abstract]. J. Clin. Oncol. 44, 6060 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020232","volume":"11","author":"S Sau","year":"2019","unstructured":"Sau, S., Petrovici, A., Alsaab, H. O., Bhise, K. & Iyer, A. K. PDL-1 antibody drug conjugate for selective chemo-guided immune modulation of cancer. Cancers 11, 232 (2019).","journal-title":"Cancers"},{"key":"1209_CR126","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8611","volume":"43","author":"E Fontana","year":"2025","unstructured":"Fontana, E. et al. Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial [abstract]. J. Clin. Oncol. 43, 8611 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR127","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.6033","volume":"43","author":"ML Gillison","year":"2025","unstructured":"Gillison, M. L. et al. Initial safety and efficacy of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in combination with pembrolizumab in patients with recurrent or metastatic (R\/M) HNSCC [abstract]. J. Clin. Oncol. 43, 6033 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR128","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","volume":"19","author":"JA Scribner","year":"2020","unstructured":"Scribner, J. A. et al. Preclinical development of MGC018, a duocarmycin-based antibody\u2013drug conjugate targeting B7-H3 for solid cancer. Mol. Cancer Ther. 19, 2235\u20132244 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"1209_CR129","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2631","volume":"39","author":"S Jang","year":"2021","unstructured":"Jang, S. et al. Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors [abstract]. J. Clin. Oncol. 39, 2631 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR130","unstructured":"GSK. GSK\u2019s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population. GSK https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-s-licensor-hansoh-pharma-announces-positive-phase-iii-results-for-ris-rez-in-china-patient-population (2026)."},{"key":"1209_CR131","doi-asserted-by":"publisher","first-page":"S485","DOI":"10.1016\/j.annonc.2024.08.673","volume":"35","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced\/metastatic solid tumors [abstract 606O]. Ann. Oncol. 35, S485\u2013S486 (2024).","journal-title":"Ann. Oncol."},{"key":"1209_CR132","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007572","volume":"11","author":"E Gray","year":"2023","unstructured":"Gray, E. et al. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models. J. Immunother. Cancer 11, e007572 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1209_CR133","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1158\/2767-9764.CRC-24-0248","volume":"4","author":"JP Gallant","year":"2024","unstructured":"Gallant, J. P. et al. Mechanistic characterization of cancer-associated fibroblast depletion via an antibody\u2013drug conjugate targeting fibroblast activation protein. Cancer Res. Commun. 4, 1481\u20131494 (2024).","journal-title":"Cancer Res. Commun."},{"key":"1209_CR134","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-19-2238","volume":"26","author":"M Fabre","year":"2020","unstructured":"Fabre, M. et al. OMTX705, a novel FAP-targeting ADC demonstrates activity in chemotherapy and pembrolizumab-resistant solid tumor models. Clin. Cancer Res. 26, 3420\u20133430 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1209_CR135","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5682","volume":"65","author":"J Solek","year":"2024","unstructured":"Solek, J., Braun, M., Sadej, R. & Romanska, H. M. FGFR-related phenotypic and functional profile of CAFs in prognostication of breast cancer (Review). Int. J. Oncol. 65, 94 (2024).","journal-title":"Int. J. Oncol."},{"key":"1209_CR136","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1158\/1535-7163.MCT-21-0335","volume":"20","author":"S Tsujii","year":"2021","unstructured":"Tsujii, S. et al. Glypican-1 is a novel target for stroma and tumor cell dual-targeting antibody\u2013drug conjugates in pancreatic cancer. Mol. Cancer Ther. 20, 2495\u20132505 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"1209_CR137","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1158\/1535-7163.MCT-15-0188","volume":"14","author":"A Visintin","year":"2015","unstructured":"Visintin, A. et al. Novel anti-TM4SF1 antibody\u2013drug conjugates with activity against tumor cells and tumor vasculature. Mol. Cancer Ther. 14, 1868\u20131876 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"1209_CR138","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1158\/1535-7163.MCT-14-0599","volume":"13","author":"T List","year":"2014","unstructured":"List, T., Casi, G. & Neri, D. A chemically defined trifunctional antibody\u2013cytokine\u2013drug conjugate with potent antitumor activity. Mol. Cancer Ther. 13, 2641\u20132652 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"1209_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/biom10030360","volume":"10","author":"H Shim","year":"2020","unstructured":"Shim, H. Bispecific antibodies and antibody\u2013drug conjugates for cancer therapy: technological considerations. Biomolecules 10, 360 (2020).","journal-title":"Biomolecules"},{"key":"1209_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490911","volume":"15","author":"O Nolan-Stevaux","year":"2024","unstructured":"Nolan-Stevaux, O. & Smith, R. Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies. Front. Immunol. 15, 1490911 (2024).","journal-title":"Front. Immunol."},{"key":"1209_CR141","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009710","volume":"12","author":"Y Dong","year":"2024","unstructured":"Dong, Y. et al. Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses. J. Immunother. Cancer 12, e009710 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1209_CR142","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma, Y. et al. BL-B01D1, a first-in-class EGFR\u2013HER3 bispecific antibody\u2013drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 25, 901\u2013911 (2024).","journal-title":"Lancet Oncol."},{"key":"1209_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03792-7","author":"C Liu","year":"2025","unstructured":"Liu, C. et al. A bispecific antibody\u2013drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-03792-7 (2025).","journal-title":"Nat. Med."},{"key":"1209_CR144","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.4008","volume":"44","author":"Z Lu","year":"2026","unstructured":"Lu, Z. et al. Izalontamab brengitecan (iza-bren) versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC): a multicenter, randomized, open-label, phase III study [abstract]. J. Clin. Oncol. 44, 4008 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR145","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S0140-6736(25)01954-3","volume":"406","author":"Y Yang","year":"2025","unstructured":"Yang, Y. et al. Izalontamab brengitecan, an EGFR and HER3 bispecific antibody\u2013drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China. Lancet 406, 2235\u20132243 (2025).","journal-title":"Lancet"},{"key":"1209_CR146","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1091\/mbc.01-08-0409","volume":"13","author":"BA Rous","year":"2002","unstructured":"Rous, B. A. et al. Role of adaptor complex AP-3 in targeting wild-type and mutated CD63 to lysosomes. Mol. Biol. Cell 13, 1071\u20131082 (2002).","journal-title":"Mol. Biol. Cell"},{"key":"1209_CR147","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1158\/1535-7163.MCT-16-0364","volume":"15","author":"BECG de Goeij","year":"2016","unstructured":"de Goeij, B. E. C. G. et al. Efficient payload delivery by a bispecific antibody\u2013drug conjugate targeting HER2 and CD63. Mol. Cancer Ther. 15, 2688\u20132697 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"1209_CR148","doi-asserted-by":"publisher","first-page":"34296","DOI":"10.1074\/jbc.M109.039727","volume":"284","author":"A Tuli","year":"2009","unstructured":"Tuli, A. et al. Mechanism for amyloid precursor-like protein 2 enhancement of major histocompatibility complex class I molecule degradation. J. Biol. Chem. 284, 34296\u201334307 (2009).","journal-title":"J. Biol. Chem."},{"key":"1209_CR149","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1021\/acs.bioconjchem.7b00013","volume":"28","author":"RM DeVay","year":"2017","unstructured":"DeVay, R. M. et al. Improved lysosomal trafficking can modulate the potency of antibody drug conjugates. Bioconjug. Chem. 28, 1102\u20131114 (2017).","journal-title":"Bioconjug. Chem."},{"key":"1209_CR150","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","volume":"14","author":"Y Gu","year":"2024","unstructured":"Gu, Y., Wang, Z. & Wang, Y. Bispecific antibody drug conjugates: making 1+1>2. Acta Pharm. Sin. B 14, 1965\u20131986 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"1209_CR151","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.biomaterials.2018.06.017","volume":"178","author":"J Lai","year":"2018","unstructured":"Lai, J. et al. Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1. Biomaterials 178, 158\u2013169 (2018).","journal-title":"Biomaterials"},{"key":"1209_CR152","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1158\/2159-8290.CD-22-1074","volume":"13","author":"T Hattori","year":"2023","unstructured":"Hattori, T. et al. Creating MHC-restricted neoantigens with covalent inhibitors that can be targeted by immune therapy. Cancer Discov. 13, 132\u2013145 (2023).","journal-title":"Cancer Discov."},{"key":"1209_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20163912","volume":"20","author":"Y Shen","year":"2019","unstructured":"Shen, Y. et al. The antitumor activity of TCR-mimic antibody-drug conjugates (TCRm-ADCs) targeting the intracellular wilms tumor 1 (WT1) oncoprotein. Int. J. Mol. Sci. 20, 3912 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1209_CR154","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","volume":"2","author":"SE Ackerman","year":"2021","unstructured":"Ackerman, S. E. et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat. Cancer 2, 18\u201333 (2021).","journal-title":"Nat. Cancer"},{"key":"1209_CR155","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.2538","volume":"41","author":"BT Li","year":"2023","unstructured":"Li, B. T. et al. A phase 1\/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors [abstract]. J. Clin. Oncol. 41, 2538 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR156","first-page":"A244","volume":"8","author":"M Sharma","year":"2020","unstructured":"Sharma, M. et al. Phase 1\/2 study of novel HER2-targeting, TLR7\/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors [abstract 401]. J. Immunother. Cancer 8, A244 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1209_CR157","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2549","volume":"39","author":"M Sharma","year":"2021","unstructured":"Sharma, M. et al. Preliminary results from a phase 1\/2 study of BDC-1001, a novel HER2 targeting TLR7\/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors [abstract]. J. Clin. Oncol. 39, 2549 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR158","doi-asserted-by":"publisher","first-page":"S450","DOI":"10.1016\/j.annonc.2021.08.491","volume":"32","author":"SJ Klempner","year":"2021","unstructured":"Klempner, S. J. et al. Interim results of a phase I\/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors [abstract 209P]. Ann. Oncol. 32, S450 (2021).","journal-title":"Ann. Oncol."},{"key":"1209_CR159","doi-asserted-by":"publisher","first-page":"15716","DOI":"10.1021\/acs.jmedchem.1c00961","volume":"64","author":"L He","year":"2021","unstructured":"He, L. et al. Immune modulating antibody\u2013drug conjugate (IM-ADC) for cancer immunotherapy. J. Med. Chem. 64, 15716\u201315726 (2021).","journal-title":"J. Med. Chem."},{"key":"1209_CR160","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-3503","volume":"82","author":"JR Duvall","year":"2022","unstructured":"Duvall, J. R. et al. XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab or pertuzumab [abstract]. Cancer Res. 82, 3503 (2022).","journal-title":"Cancer Res."},{"key":"1209_CR161","first-page":"A751","volume":"12","author":"EE Dumbrava","year":"2024","unstructured":"Dumbrava, E. E. et al. XMT-2056: a phase 1 study of a HER2-directed STING agonist antibody drug conjugate (ADC) in HER2+ solid tumors [abstract 654]. J. Immunother. Cancer 12, A751 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1209_CR162","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"NWCJ van de Donk","year":"2023","unstructured":"van de Donk, N. W. C. J. & Zweegman, S. T-cell-engaging bispecific antibodies in cancer. Lancet 402, 142\u2013158 (2023).","journal-title":"Lancet"},{"key":"1209_CR163","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1021\/jacs.5b00620","volume":"137","author":"RE Wang","year":"2015","unstructured":"Wang, R. E. et al. An immunosuppressive antibody\u2013drug conjugate. J. Am. Chem. Soc. 137, 3229\u20133232 (2015).","journal-title":"J. Am. Chem. Soc."},{"key":"1209_CR164","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-1832","volume":"81","author":"SK Mitra","year":"2021","unstructured":"Mitra, S. K. et al. Development of a splicing modulator-based ADC payload class with immune stimulatory properties for cancer therapy [abstract]. Cancer Res. 81, 1832 (2021).","journal-title":"Cancer Res."},{"key":"1209_CR165","first-page":"124","volume":"8","author":"Y Cheng","year":"2025","unstructured":"Cheng, Y. et al. Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors. Antib. Ther. 8, 124\u2013144 (2025).","journal-title":"Antib. Ther."},{"key":"1209_CR166","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1158\/0008-5472.CAN-24-2021","volume":"85","author":"Q Wei","year":"2025","unstructured":"Wei, Q. et al. Perivascular niche\u2013resident alveolar macrophages promote interstitial pneumonitis related to trastuzumab deruxtecan treatment. Cancer Res. 85, 2081\u20132099 (2025).","journal-title":"Cancer Res."},{"key":"1209_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-026-01188-1","author":"S Peters","year":"2026","unstructured":"Peters, S., Grivas, P., Massard, C., Tolaney, S. M. & Obeid, M. Clinical toxicity of ADCs and ICI\u2013ADC combinations: mechanisms, patterns and management. Nat. Rev. Clin. Oncol. https:\/\/doi.org\/10.1038\/s41571-026-01188-1 (2026).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1209_CR168","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1326715","volume":"14","author":"B Brower","year":"2024","unstructured":"Brower, B. et al. Managing potential adverse events during treatment with enfortumab vedotin\u2009+\u2009pembrolizumab in patients with advanced urothelial cancer. Front. Oncol. 14, 1326715 (2024).","journal-title":"Front. Oncol."},{"key":"1209_CR169","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41416-022-01894-4","volume":"127","author":"J Marinello","year":"2022","unstructured":"Marinello, J. et al. Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS\/STING pathway. Br. J. Cancer 127, 1214\u20131225 (2022).","journal-title":"Br. J. Cancer"},{"key":"1209_CR170","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde, P. S. & Chen, D. S. Top 10 challenges in cancer immunotherapy. Immunity 52, 17\u201335 (2020).","journal-title":"Immunity"},{"key":"1209_CR171","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321\u2013330 (2017).","journal-title":"Nature"},{"key":"1209_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102614","volume":"120","author":"M Borgeaud","year":"2023","unstructured":"Borgeaud, M. et al. Novel targets for immune-checkpoint inhibition in cancer. Cancer Treat. Rev. 120, 102614 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"1209_CR173","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s43018-026-01181-8","volume":"7","author":"P Schmid","year":"2026","unstructured":"Schmid, P. et al. First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b\/2 BEGONIA platform trial. Nat. Cancer 7, 983\u2013992 (2026).","journal-title":"Nat. Cancer"},{"key":"1209_CR174","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.511","volume":"43","author":"RO Abelman","year":"2025","unstructured":"Abelman, R. O. et al. A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG\/P) in patients with early-stage triple-negative breast cancer: results from the NeoSTAR trial [abstract]. J. Clin. Oncol. 43, 511 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR175","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.22.02835","volume":"42","author":"P Grivas","year":"2024","unstructured":"Grivas, P. et al. Sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer that progressed after platinum-based chemotherapy: TROPHY-U-01 cohort 3. J. Clin. Oncol. 42, 1415\u20131425 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.10.016","volume":"21","author":"M Reck","year":"2026","unstructured":"Reck, M. et al. First-line sacituzumab govitecan plus pembrolizumab in metastatic NSCLC: PD-L1 TPS less than 50% and more than or equal to 50% cohorts of the EVOKE-02 study. J. Thorac. Oncol. 21, 103509 (2026).","journal-title":"J. Thorac. Oncol."},{"key":"1209_CR177","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1038\/s41591-025-03746-z","volume":"31","author":"T Cascone","year":"2025","unstructured":"Cascone, T. et al. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial. Nat. Med. 31, 2788\u20132796 (2025).","journal-title":"Nat. Med."},{"key":"1209_CR178","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ygyno.2025.06.016","volume":"200","author":"UA Matulonis","year":"2025","unstructured":"Matulonis, U. A. et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)\u2013targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer. Gynecol. Oncol. 200, 96\u2013104 (2025).","journal-title":"Gynecol. Oncol."},{"key":"1209_CR179","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT045","volume":"85","author":"JT Henry","year":"2025","unstructured":"Henry, J. T. et al. A phase 1\/2 trial of TAC-001 (TLR9 agonist-CD22 mAb) in advanced or metastatic solid tumors [abstract]. Cancer Res. 85, CT045 (2025).","journal-title":"Cancer Res."},{"key":"1209_CR180","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1200\/JCO-25-01957","volume":"43","author":"LE Budde","year":"2025","unstructured":"Budde, L. E. et al. Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory\/relapsed large B-cell lymphoma: primary results of the phase III SUNMO trial. J. Clin. Oncol. 43, 3799\u20133811 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1209_CR181","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1200\/JCO-25-00992","volume":"43","author":"M Hutchings","year":"2025","unstructured":"Hutchings, M. et al. Efficacy and safety of glofitamab plus polatuzumab vedotin in relapsed\/refractory large B-cell lymphoma including high-grade B-cell lymphoma: results from a phase Ib\/II trial. J. Clin. Oncol. 43, 3788\u20133798 (2025).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01209-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01209-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01209-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:01:40Z","timestamp":1795093300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01209-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":181,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1209"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01209-z","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"11 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.C. has acted as a consultant and\/or adviser of AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Boehringer Ingelheim, Celcuity, Daiichi Sankyo, Ellipses Pharma, Exact Sciences, Foundation Medicine, Gilead Sciences, GlaxoSmithKline, Guardant Health, Hengrui Therapeutics, Lilly, Menarini, Merck, Novartis, Pfizer, Roche\/Genentech, Samsung, Seagen and Veracyte; has acted as a speaker on behalf of AstraZeneca, Daiichi Sankyo, Exact Sciences, Foundation Medicine, Gilead Sciences, Lilly, Menarini, Novartis, Pfizer, Roche\/Genentech, Samsung and Seagen; has received research funding from Merck; has received travel and\/or accommodation support from AstraZeneca, Daiichi Sankyo, Pfizer and Roche\/Genentech; and has leadership roles in ESMO, the European Society of Breast Cancer Specialists and ESMO Open. L.A.C. has received institutional research funding from AstraZeneca, Gilead Sciences, Lilly, NanoString Technologies, Novartis, Pfizer, Seagen and Veracyte. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}